<DOC>
	<DOCNO>NCT02575638</DOCNO>
	<brief_summary>This single-arm , non-randomized feasibility Phase I trial 20 ( S ) Camptothecin Propionate administer orally . CZ48 administer successive cohort 1 patient per participate site hint toxicity ( grade 2 bad adverse event related drug ) observe . Then cohorts 3+3 patient treat . CZ48 administer orally daily ( 1 course = 4 week ) . No pre-medications administer . Patients ask drink one gallon fluid daily possible flush bladder mitigate cystitis . Cystitis anticipated toxicity CZ48 pro-drug CPT ( Camptothecin )</brief_summary>
	<brief_title>Safety Study Camptothecin-20-O-Propionate Hydrate ( CZ48 )</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : â€¢ To describe dose limit toxicity adverse event profile Camptothecin-20-O-Propionate hydrate ( CZ48 ) administer orally every day 4 week ( 1 course ) . SECONDARYOBJECTIVE - To determine Maximum Tolerated Dose ( MTD ) Camptothecin-20-O-Propionate hydrate ( CZ48 ) . - To determine blood plasma level ( PK study ) orally administer CZ48 . - To assess response Response Evaluation Criteria Solid Tumors ( RECIST ) criterion applicable . - To follow patient survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patients must Performance Status ( Zubrod ) performance status 01 Patients must sign informed consent document Patients adequate bone marrow function define absolute peripheral granulocyte count &gt; 1,500 /mm3 platelet count &gt; 100,000/mm3 along absence red blood cell transfusion two week prior participation trial Patients adequate hepatic function total bilirubin within normal range serum glutamate oxaloacetate transaminase ( SGOT ) serum glutamate pyruvate transaminase ( SGPT ) &lt; two time upper limit normal ( ULN ) patient without liver metastasis SGOT SGPT &lt; five time ULN liver metastasis , adequate renal function define serum creatinine within 1.5 time upper limit normal . Patients may receive concurrent anticancer treatment chemotherapy , hormone therapy ( except prostate cancer patient luteinizing hormonereleasing hormone ( ( LHRH ) ) agonist ) , immunotherapy , biological agent , investigational agent , radiation therapy trial , treatment least 2 week , completely recovered side effect treatment , whichever long , except persistent grade 1 neuropathy patient receive prior platinum taxanes . Patients symptomatic brain metastasis exclude study . Patients brain metastasis treat , asymptomatic steroid use permit study Pregnant woman nurse mother eligible trial . Patients child bear potential must use adequate contraception ( contraceptive pill , intrauterine device ( ( IUD ) ) , two mechanical barrier ) . Patients severe uncontrolled medical problem eligible trial . Patients much esterase determine prescreen dose , conversion rate yield concentration CPT &gt; 100 ng/ml vitro .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>